Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study
- 1 March 2018
- journal article
- research article
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 37 (3) , 401-408
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag an oral prostacyclin receptor agonist and its active metabolite in healthy subjectsBritish Journal of Clinical Pharmacology, 2015
- Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist SelexipagAmerican Journal of Cardiovascular Drugs, 2015
- Parenteral and Inhaled Prostanoid Therapy in the Treatment of Pulmonary Arterial HypertensionClinics in Chest Medicine, 2013
- Current and Emerging Therapies in Pulmonary Arterial Hypertension: Focus on TreprostinilClinical Medicine Reviews in Vascular Health, 2011
- 2-{4-[(5,6-Diphenylpyrazin-2-yl)(isopropyl)amino]butoxy}-N-(methylsulfonyl)acetamide (NS-304), an Orally Available and Long-Acting Prostacyclin Receptor Agonist ProdrugThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Treatment of Pulmonary Arterial HypertensionNew England Journal of Medicine, 2004
- Cellular and molecular pathobiology of pulmonary arterial hypertensionJACC, 2004
- Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin.Heart, 1997
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol)Annals of Internal Medicine, 1990